Your browser is no longer supported. Please, upgrade your browser.
SEEL Seelos Therapeutics, Inc. daily Stock Chart
Seelos Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own7.20% Shs Outstand44.95M Perf Week-15.70%
Market Cap49.99M Forward P/E- EPS next Y-0.42 Insider Trans0.00% Shs Float37.93M Perf Month-8.93%
Income-20.60M PEG- EPS next Q-0.14 Inst Own12.40% Short Float1.76% Perf Quarter142.91%
Sales0.40M P/S124.98 EPS this Y-123.80% Inst Trans87.73% Short Ratio0.43 Perf Half Y-24.44%
Book/sh0.20 P/B5.10 EPS next Y20.90% ROA-159.00% Target Price- Perf Year-50.96%
Cash/sh0.26 P/C3.94 EPS next 5Y- ROE-373.30% 52W Range0.42 - 2.25 Perf YTD-23.88%
Dividend- P/FCF- EPS past 5Y56.90% ROI- 52W High-54.67% Beta1.90
Dividend %- Quick Ratio2.00 Sales past 5Y-47.30% Gross Margin- 52W Low143.15% ATR0.15
Employees6 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)44.82 Volatility10.64% 12.29%
OptionableNo Debt/Eq0.00 EPS Q/Q96.40% Profit Margin- Rel Volume0.43 Prev Close1.06
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.57M Price1.02
Recom2.00 SMA20-16.01% SMA504.02% SMA2007.18% Volume670,889 Change-3.77%
Nov-14-19Initiated The Benchmark Company Speculative Buy $4
May-14-19Initiated ROTH Capital Buy
Jun-25-20 08:00AM  
Jun-23-20 07:00AM  
Jun-17-20 09:08AM  
Jun-15-20 08:01AM  
Jun-04-20 07:26PM  
May-28-20 07:01AM  
May-19-20 11:42AM  
May-18-20 08:01AM  
May-15-20 10:30AM  
May-12-20 08:05AM  
May-04-20 08:01AM  
Apr-30-20 01:31PM  
Apr-08-20 09:01AM  
Mar-24-20 08:01AM  
Mar-16-20 04:30PM  
Mar-11-20 08:30PM  
Mar-06-20 08:01AM  
Feb-26-20 08:01AM  
Feb-19-20 08:02AM  
Feb-17-20 08:57AM  
Feb-13-20 04:30PM  
Feb-10-20 08:00PM  
Jan-28-20 01:58PM  
Jan-22-20 07:30AM  
Jan-10-20 08:30AM  
Jan-06-20 08:02AM  
Dec-16-19 07:00AM  
Dec-13-19 08:30AM  
Dec-04-19 08:00AM  
Nov-30-19 10:18AM  
Nov-27-19 11:00AM  
Nov-20-19 09:00AM  
Nov-18-19 08:00AM  
Nov-08-19 07:00AM  
Nov-01-19 10:00AM  
Oct-21-19 09:00AM  
Oct-18-19 09:00AM  
Oct-15-19 09:00AM  
Sep-04-19 09:00AM  
Aug-23-19 09:00AM  
Aug-22-19 02:24PM  
Aug-14-19 06:00PM  
Aug-06-19 09:00AM  
Aug-01-19 09:00AM  
Jul-17-19 09:00AM  
Jul-15-19 11:00AM  
Jul-02-19 11:00AM  
Jul-01-19 09:00AM  
Jun-28-19 11:38AM  
Jun-27-19 07:00AM  
Jun-06-19 07:00AM  
May-21-19 08:30AM  
Apr-16-19 08:00AM  
Apr-02-19 01:15PM  
Mar-29-19 02:43PM  
Mar-28-19 05:00PM  
Mar-27-19 09:25AM  
Mar-13-19 07:30AM  
Mar-08-19 09:37AM  
Mar-07-19 08:00AM  
Mar-06-19 02:45PM  
Mar-01-19 09:00AM  
Feb-19-19 08:00AM  
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with Parkinson's disease or Lewy Body Dementia; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and orphan indications; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. The company was founded in 2016 and is headquartered in New York, New York.